David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and current Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. He has twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis and in 2023, the UChicago Michael Reese Lectureship Award for outstanding faculty who have developed novel teaching and clinical research that advances healthcare, and separately, the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. He is Editor-in-Chief of the ACG On-Line Education Universe. Dr. Rubin is an editor of Curbside Consultation in IBD (3rd ed), senior editor of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (12th ed), and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Practice Guidelines for ulcerative colitis.
University of Chicago Pritzker School of Medicine
Chicago
Fellowship - Gastroenterology
2001
University of Chicago Pritzker School of Medicine
Chicago
Residency - Internal Medicine
1997
University of Chicago Pritzker School of Medicine
Chicago
MD
1994
University of Illinois
Urbana-Champaign
BS - Honors Biology
1990
Wearable perspiration sensor for continuous inflammation tracking in inflammatory bowel disease.
Wearable perspiration sensor for continuous inflammation tracking in inflammatory bowel disease. Inflamm Bowel Dis. 2026 Nov 01; 32(11):2095-2102.
PMID: 42665275
Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI.
Intravenous Versus Subcutaneous Induction with Guselkumab: Week 12 and Week 96 Efficacy in GALAXI 2 & 3 and GRAVITI. Clin Gastroenterol Hepatol. 2026 Oct 27.
PMID: 42946108
Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study.
Efficacy and Safety of Guselkumab in Patients with Crohn's Disease and Ulcerative Colitis: A Prospective Real-World Study. Clin Gastroenterol Hepatol. 2026 Oct 22.
PMID: 42913902
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD.
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD. Lancet Gastroenterol Hepatol. 2026 Oct 19.
PMID: 42896564
Building a Better Model for Fecal Calprotectin Monitoring in Inflammatory Bowel Disease: Room for Some Home Improvement.
Building a Better Model for Fecal Calprotectin Monitoring in Inflammatory Bowel Disease: Room for Some Home Improvement. Gastroenterology. 2026 Oct 16.
PMID: 42887790
Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis.
Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis. ACG Case Rep J. 2026 Sep; 13(9):e02290.
PMID: 42746618
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. Inflamm Bowel Dis. 2026 Sep 01; 32(9):1669-1682.
PMID: 42065683
Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds.
Ultrasound criteria for transmural healing and response in Crohn's disease: a systematic review of definitions and thresholds. Inflamm Bowel Dis. 2026 Sep 01; 32(9):1707-1721.
PMID: 42222916
Negotiated Prices for Reconstructive Surgery Converge without Reduction in Overall Price Level after Federal Price Transparency Regulations.
Negotiated Prices for Reconstructive Surgery Converge without Reduction in Overall Price Level after Federal Price Transparency Regulations. J Am Coll Surg. 2026 Aug 25.
PMID: 42640626
Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design.
Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design. Clin Exp Gastroenterol. 2026; 19:603005.
PMID: 42657205